dual agonist raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-04-12. Anything still debated is marked as such rather than presented as settled.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 39-residue peptide | GIP-derived backbone with non-natural residues |
| Molar mass | Approximately 4.8 kDa | Peptide chain plus linker and lipid modifications |
| Appearance | White to off-white powder | Typical of lyophilized research material |
| Solubility | Soluble in water and aqueous buffer | Practically insoluble in nonpolar solvents |
| Storage temperature | Typically −20 °C for dry powder | Solutions usually held at 2–8 °C short term |
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Current medical guidelines recommend testing tissue transglutaminase 2 immunoglobulin A (TTG IgA) in those with suspected coeliac disease. Because IgA deficiency is more common in those with coeliac disease, guidelines recommend testing for IgA deficiency as a part of the diagnostic workup for coeliac disease. If an individual with IgA deficiency is getting tested for coeliac disease, immunoglobulin G (IgG) based tests such as deamidated gliadin peptide IgG (DGP IgG) or endomysial antibody (EMA) can be used instead of IgA-based tests. Antigliadin antibodies (AGA) and antireticulin antibodies (ARA) were historically used to test for coeliac disease; however, due to the development of more accurate tests, they are no longer recommended. Due to the risk of false positive or negative serological tests and the consequences of leaving coeliac disease untreated or introducing unnecessary dietary restrictions. In the case of a false positive, biopsies are used to confirm the diagnosis regardless of blood test results. TG2 IgA has a high sensitivity (92.8%) and specificity (97.9%), and is cost-efficient and widely available, making it the first choice for serological tests in the diagnosis of coeliac disease. Performance of the TG2 IgA test differs between labs and no formal standardisation between assays exists. The severity of small intestine damage generally correlates with the levels of TG2 IgA found in the blood, meaning that the sensitivity is lower in people who have less damage to their intestines.
== Early life and education == Shiva Ayyadurai was born Vellayappa Ayyadurai Shiva in 1963, in Bombay (now Mumbai), India. He grew up in the Muhavur village in Rajapalayam, Tamil Nadu. At the age of seven, he left with his family to live in the United States. He was raised in Livingston, New Jersey. In 1978, as a 14-year-old high school student, Ayyadurai attended a summer program at the Courant Institute of Mathematical Sciences of New York University (NYU) to study computer programming. While a student at Livingston High School in New Jersey, Ayyadurai volunteered at the University of Medicine and Dentistry of New Jersey (UMDNJ) where his mother worked. While there Leslie Michelson asked him to set up an electronic messaging system for 100 users at the medical school. In 1982, he registered the copyright for the source code and user documentation of the FORTRAN program called EMAIL. Ayyadurai's undergraduate degree from MIT was in electrical engineering and computer science; he took a master's degree in visual studies from the MIT Media Laboratory on scientific visualization; concurrently, he completed another master's degree in mechanical engineering, also from MIT; and in 2007, he obtained a PhD in biological engineering from MIT in systems biology, with his thesis focusing on modeling the whole cell by integrating molecular pathway models. In 2007, he was awarded a Fulbright U.S. Student Program grant to study the integration of Siddha, a system of traditional medicine developed in South India, with modern systems biology.
This was a boom year with a record high in exports, but the Scotch Whisky Association expressed concern for the future, particularly "the challenges posed by Brexit and by tensions in the global trading system". Scotch whisky tourism has developed around the industry, with distilleries being the third most visited attraction in Scotland; roughly 2 million visits were recorded in 2018. Some 68 distilleries operate visitors' centres in Scotland and another eight accept visits by appointment. Hotels, restaurants, and other facilities are also impacted by the tourism phenomenon. Tourism has had an especially visible impact on the economy in some remote rural areas, according to Fiona Hyslop MSP, Cabinet Secretary for Culture, Tourism and External Affairs: "The Scottish Government is committed to working with partners like the Scotch Whisky Association to increase our tourism offer and encourage more people to visit our distilleries." During the COVID-19 pandemic, exports of many food and drink products from the UK declined significantly, and that included Scotch whisky. Distillers were required to close for some time and the hospitality industry worldwide experienced a major slump. According to news reports in February 2021, the Scotch whisky sector had experienced £1.1 billion in lost sales. Exports to the US were also affected by the 25% tariff that had been imposed. Scotch whisky exports to the US during 2020 reportedly fell by 32% from the previous year. Worldwide exports fell in 70% of Scotch whisky's global markets.
Sources: en.wikipedia.org
Like the lanthanides, the actinides form a family of elements with similar properties. Within the actinides, there are two overlapping groups: transuranium elements, which follow uranium in the periodic table, and transplutonium elements, which follow plutonium. Compared to the lanthanides, which (except for promethium) are found in nature in appreciable quantities, most actinides are rare. Most do not occur in nature, and of those that do, only thorium and uranium do so in more than trace quantities. The most abundant or easily synthesized actinides are uranium and thorium, followed by plutonium, americium, actinium, protactinium, neptunium, and curium. The existence of transuranium elements was suggested in 1934 by Enrico Fermi, based on his experiments. However, even though four actinides were known by that time, it was not yet understood that they formed a family similar to lanthanides. The prevailing view that dominated early research into transuranics was that they were regular elements in the 7th period, with thorium, protactinium and uranium corresponding to 6th-period hafnium, tantalum and tungsten, respectively. Synthesis of transuranics gradually undermined this point of view. By 1944, an observation that curium failed to exhibit oxidation states above 4 (whereas its supposed 6th period homolog, platinum, can reach oxidation state of 6) prompted Glenn Seaborg to formulate an "actinide hypothesis".
== Side effects == Frequently reported side effects include: nausea, heartburn, weight gain, and bloating. The medication is also a major cause of medication-induced hypoglycemia. The risk is greater than with other sulfonylureas.
=== Beauty supplements === Beauty supplements, particularly those aimed at improving the health of skin, hair, and nails, are commonly marketed within the wellness and supplement markets. These products typically include ingredients, such as collagen, which is reputed to improve the appearance and condition of skin, hair, and nails. Other typical ingredients include biotin, keratin, and omega-3 fatty acids, which are promoted for their alleged benefits to skin and hair health. Demand for these beauty supplements has risen markedly in the 21st century. Despite the apparent rise in demand, scientific evidence supporting the efficacy of ingredients like biotin for the purpose of hair growth remains unproven.
Sources: en.wikipedia.org
It acts as an agonist at both the GIP and GLP-1 receptors, two related class B G protein-coupled receptors. This dual activity distinguishes it from single-receptor GLP-1 agonists. The clinical consequences of engaging both receptors are still being characterized.
It is given by subcutaneous injection, generally on a weekly schedule. Dosing usually begins low and increases in steps to limit gastrointestinal side effects. Formulated product is supplied as a ready-to-use pen or vial in most markets.
No. Receptor engagement is documented, but how central appetite circuits, gut signals, and insulinotropic effects combine is incompletely resolved. Investigators continue to separate GIP-driven from GLP-1-driven contributions in animal and human models.
Water promotes hydrolysis and deamidation, so removing it slows degradation during transport and storage. The dry solid is also less prone to microbial growth than a solution. Reconstitution is therefore performed close to the point of use.